Quarterly Earnings

Ealixir's Q2 results reveal a narrowing loss and revenue jump, driven by its new AI engine EALUMINATE and a strategic, scalable move into Italian media.

As Enterprise Products meets investors, it's not just about record profits. It's a dialogue on trust, transition, and the future of America's energy backbone.

As Johnson & Johnson prepares for a key investor conference, its strategy hinges on a potent mix of new drugs, robotic surgery, and a leaner focus.

With a strong cash runway, Nkarta pushes its off-the-shelf NK cell therapy into community clinics, setting the stage for a pivotal data reveal in 2026.

With promising early data and a robust balance sheet, Palisade Bio is advancing its targeted IBD therapy, PALI-2108, into crucial Phase 2 trials.

FutureFuel's stunning $25.6M profit swing reveals a blueprint for resilience, powered by regulatory tailwinds in biofuels and reshoring in chemicals.

Amplify Energy touts a major profit swing and a new stock buyback, but a look under the hood reveals a complex picture of derivative gains and real-world challenges.

Amid Q2 losses, Proficient Auto Logistics acquires Hansen & Adkins, betting big on consolidation to navigate an auto haul industry facing an 'inflection point'.

With major clinical trials progressing and a $110M war chest, Orchestra BioMed is orchestrating a potential shift in cardiovascular treatment.

Getty Images faces a liquidity crisis with soaring debt and a failed merger, raising doubts about its future despite some growth in its core business.

Beyond the hype of AI models and drones, Kopin is building the critical optical networks and displays that make them possible. A look at its strategic Q2.

P3 Health Partners stuns Wall Street with a swing to profitability, but a deeper dive reveals one-time gains and a strategic pivot. Is this the new playbook?

Amidst declining revenue and layoffs, Rapid7's new CEO is making a bold bet on a focused, AI-driven strategy. Is this the path to renewed strength?

BODi posts a fourth straight profitable quarter, but with revenue and subscribers in freefall, is its dramatic cost-cutting a sign of health or stagnation?

Shimmick Corp. posts improving financials and a record backlog, but a closer look reveals the high cost of its strategic pivot from troubled legacy projects.

Sumisho Air Lease reports a 98% profit drop in its first post-acquisition quarter, but accounting shifts mask a deeper strategic realignment for the lessor.

Tactile Medical's impressive Q2 profit growth is tempered by a product launch stumble, testing its execution as it places big bets on new markets and tech.

Metagenomi Therapeutics is on track for a pivotal 2027 clinical trial, but its advanced gene editing tech faces a market wary of high-cost cures.

Insight Molecular Diagnostics has key regulatory and reimbursement wins for its game-changing transplant test, but a high cash burn creates a high-stakes race to commercialization.

Alico's Q3 results reveal a successful pivot from citrus giant to land developer, with profits soaring and major projects advancing. How is this changing Florida?